IL13 and eosinophilic esophagitis: In 2022, an IgG4 monoclonal antibody, dupilumab, targeting the IL-4 receptor alpha and reducing IL-4 and IL-13 signaling, was approved by the US FDA as the first therapy specifically for EoE [43].